ClinVar Miner

Submissions for variant NM_001204.7(BMPR2):c.353G>A (p.Cys118Tyr) (rs1085307216)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001000181 SCV001156674 likely pathogenic none provided 2019-09-04 criteria provided, single submitter clinical testing The BMPR2 c.353G>A; p.Cys118Tyr variant (rs1085307216) is reported in the literature in several individuals affected with pulmonary arterial hypertension (PAH) (Machado 2006, Pfarr 2011). This variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. The cysteine at codon 118 is moderately conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Other amino acid substitutions at this codon and the adjacent cysteine (p.Cys117Tyr, p.Cys118Trp, p.Cys118Ser) have been reported in individuals with PAH and are considered disease-causing (Barozzi 2019, Machado 2006). Further, functional assays indicate that several of these other substitutions (p.Cys117Tyr and p.Cys118Trp) are mislocalized in the cell and exhibit signaling defects (Rudarakanchana 2002, Sobolewski 2008). Based on available information, the p.Cys118Tyr variant is considered to be likely pathogenic. References: Barozzi C et al. A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension. Sci Rep. 2019 Jan 24;9(1):753. Machado RD et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006 Feb;27(2):121-32. Pfarr N et al. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res. 2011 Jul 29;12:99. Rudarakanchana N et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002 Jun 15;11(13):1517-25. Sobolewski A et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum Mol Genet. 2008 Oct 15;17(20):3180-90.
Medical & Molecular Genetics Group,University of Lincoln RCV000488604 SCV000576044 pathogenic Primary pulmonary hypertension 1 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.